Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.
Actively Recruiting
Researchers are studying HER3-DXd monotherapy in adults with locally advanced unresectable or metastatic solid tumors that have not responded to prior treatments. This proof-of-concept phase 2 trial includes participants with various cancers such as melanoma, head and neck squamous cell carcinoma, HER2-negative gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, lung cancer, and breast cancer. The study aims to assess how well HER3-DXd works and its safety in these cancers, also exploring the relationship between HER3 protein levels in tumors and treatment response. Participants will receive an intravenous infusion of HER3-DXd at a dose of 5.6 mgkg every three weeks. Treatment continues until disease progression, unacceptable side effects, or withdrawal. The study involves multiple cohorts, each with specific tumor types, and includes monitoring of drug levels in the blood, safety evaluations, and assessments of tumor response over approximately 27 months. During the trial, participants will undergo regular clinical evaluations, imaging scans such as CT or MRI to measure tumor lesions, and laboratory tests. Investigators will assess objective response rates, progression-free survival, overall survival, and treatment-emergent adverse events. Prostate cancer participants will have additional monitoring of prostate-specific antigen PSA levels. The study includes pharmacokinetic analyses of HER3-DXd and long-term follow-up to evaluate treatment effects and safety throughout the participation period.
Actively Recruiting
Healthy Volunteer
Snake bites affect thousands of people in Australia each year, with few deaths due to timely medical care and quality first aid. This research investigates and compares two first aid methodsthe Pressure Bandage Immobilisation PBI technique currently recommended in Australia and a simpler Pressure Pad PP technique used internationally. The study aims to determine if the PP method is as effective as PBI in slowing venom movement through the body, which is important for improving first aid guidance. Participants will receive an injection of mock venom in the hand or foot, followed by application of either no first aid, the PBI method, or the PP method. Each technique involves specific bandaging and splinting to immobilize the limb, with pressure carefully controlled around 60mmHg. The study will monitor the flow of the mock venom in each case using nuclear medicine imaging to track its movement through the lymphatic system. During the study, participants will undergo repeated scans to observe how quickly the mock venom reaches regional lymph nodes, with each person experiencing all possible combinations of injection site and first aid method in random order. The primary measure is the time taken for the venom to travel to lymph nodes, monitored over a period spanning a minimum of 12 weeks to a maximum of 18 months. This detailed data will help assess the effectiveness and safety of these first aid techniques to inform future recommendations.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes Rina-S when used alone to treat adults with locally advanced or metastatic non-small cell lung cancer NSCLC, specifically adenocarcinoma type. This Phase 2, open-label study includes participants who have cancer resistant to prior treatments and may or may not have certain genetic changes. The study is conducted worldwide with up to about 240 participants. Participants will receive Rina-S through intravenous infusion as the only treatment. The treatment is given in cycles lasting 3 weeks each, with each participant expected to undergo treatment for about 12 months on average. If the cancer remains stable or improves and there are no serious problems, participants can continue treatment while the study is ongoing. Multiple visits to the study clinic occur in each cycle to receive treatment and monitoring. During the study visits, participants will have tests such as blood draws, heart activity recordings, and imaging like X-rays to monitor safety and how well Rina-S works. Researchers will measure outcomes including tumor response, disease control, progression-free survival, overall survival, drug levels in the blood, immune response to the drug, and side effects. Participation may last several years, with key outcome assessments spanning up to about four years after starting treatment.